LG Chem Announces Initiation of Two Phase 2 Trials (ROUTE & SIGNAL) of Novel Oral MC4R Agonist LB54640 in Patients with Rare Forms of Genetic Obesity
SEOUL, South Korea, May 15, 2023 /PRNewswire/ -- LG Chem today announced its business strategy to leap up to become a top global battery materials company and its plans for its three new growth engines by 2030.
SEOUL, South Korea, April 20, 2023 /PRNewswire/ -- Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement on Thursday, April 20th, for development of novel mRNA-based cancer therapeutics that utilizes Samyang's proprietary drug delivery technology.
Korea’s LG Chem is stepping up to the plate with a deal to manufacture essential vaccines for millions of infants and children.
LG Chem’s New US Acquisition AVEO Oncology Sets Sights On Being Global Top 20 Innovative Oncology Company
More than 12 years ago, Aveo Oncology vaulted onto Nasdaq with an IPO pitch centered on its lead cancer drug, tivozanib. It took almost a decade, with an FDA rejection, multiple shareholder lawsuits and an SEC investigation along the way, but the biotech finally clinched an approval in the US last year.
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
LG Chem recently announced that the Company has submitted an IND application to the US FDA for its first independent global Phase 3 clinical trial of its new gout drug ‘Tigulixostat’ (clinical program name: EURELIA_1 Study). LG Chem’s strategy is to expand its life sciences business and to reach global markets such as the U.S. and Europe in various therapeutic areas in the upcoming years.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LG Chem recently announced the enrollment of first subject in Phase 1 clinical trial of LG203003, LG Chem’s second NASH (non-alcoholic steatohepatitis) drug in development.